State Street SPDR S&P Pharmaceuticals ETF
XPH
72 hedge funds and large institutions have $115M invested in State Street SPDR S&P Pharmaceuticals ETF in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 10 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
1% less funds holding
Funds holding: 73 → 72 (-1)
3.45% less ownership
Funds ownership: 55.18% → 51.73% (-3.4%)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
31% less call options, than puts
Call options by funds: $957K | Put options by funds: $1.38M
43% less capital inflows, than outflows
Capital inflows: $15M | Capital outflows: $26.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$4.99M |
| 2 |
Goldman Sachs
New York
|
+$2.4M |
| 3 |
LPL Financial
San Diego,
California
|
+$2.23M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$9.21M |
| 2 |
Morgan Stanley
New York
|
-$8.96M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$4.04M |
| 4 |
Taconic Capital Advisors
New York
|
-$1.66M |
| 5 |
AE Wealth Management
Topeka,
Kansas
|
-$615K |
XPH Hedge Fund Activity: Q1 2024 in Review
72 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2024, worth a combined $115M — down 5.6% from $122M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XPH and 8 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 23 added.
The largest buyer was Kingsview Wealth Management, adding an estimated $4.99M. The largest seller was Bank of America, cutting an estimated $9.21M.
- 72 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2024, down from 73 in Q4 2023.
- Funds reported $115M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2024, down 5.6% quarter-over-quarter.
- 8 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2024 and 10 closed out, a net change of -2 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2024 was Kingsview Wealth Management, an estimated $4.99M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2024 was Bank of America, an estimated $9.21M sold.
Based on aggregated 13F filings for Q1 2024.